EyePoint (EYPT) Profit After Tax (2010 - 2026)
EyePoint (EYPT) posted Profit After Tax of -$84.8 million for Q1 2026, down 25.47% sequentially from -$67.6 million in Q4 2025, and down 87.27% YoY from -$666.2 million in Q1 2025.
EyePoint (EYPT) Profit After Tax (2010 - 2026) Analysis & Trends
EyePoint has reported Profit After Tax for 17 years, with the latest figure at -$84.8 million in Q1 2026.
- Quarterly Profit After Tax fell 87.27% year-over-year to -$84.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$271.6 million (down 85.0% YoY) and the FY2025 annual result came in at -$232.0 million, down 77.25% from the prior year.
- Profit After Tax retreated to -$84.8 million in Q1 2026 per EYPT's latest filing, from -$67.6 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$12.6 million in Q3 2023 and troughed at -$84.8 million in Q1 2026.
- A 5-year average of -$36.5 million and a median of -$29.3 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax surged 67.65% in 2023, then tumbled 196.29% in 2024.
- Over 5 years, Profit After Tax stood at -$43.5 million in 2022, then soared by 67.65% to -$14.1 million in 2023, then sank by 196.29% to -$41.7 million in 2024, then plunged by 62.11% to -$67.6 million in 2025, then retreated by 25.47% to -$84.8 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$84.8 million, -$67.6 million, and -$59.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | -94.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -94.48 Mn |
| Mar 31, 2026 | -84.83 Mn |
| Dec 31, 2025 | -67.61 Mn |
| Sep 30, 2025 | -59.73 Mn |
| Jun 30, 2025 | -59.43 Mn |
| Mar 31, 2025 | -45.30 Mn |
| Dec 31, 2024 | -41.71 Mn |
| Sep 30, 2024 | -28.98 Mn |
| Jun 30, 2024 | -30.83 Mn |
| Mar 31, 2024 | -29.28 Mn |
| Dec 31, 2023 | -14.08 Mn |
| Sep 30, 2023 | -12.61 Mn |
| Jun 30, 2023 | -22.92 Mn |
| Mar 31, 2023 | -21.16 Mn |
| Dec 31, 2022 | -43.51 Mn |
| Sep 30, 2022 | -18.42 Mn |
| Jun 30, 2022 | -19.59 Mn |
| Mar 31, 2022 | -20.98 Mn |
| Dec 31, 2021 | -19.43 Mn |
| Sep 30, 2021 | -16.70 Mn |